Why the study?
Does apixaban reduce coagulation biomarkers compared to LMWH/VKA in patients with acute deep-vein thrombosis?
Does apixaban reduce coagulation biomarkers compared to LMWH/VKA in patients with acute deep-vein thrombosis?
Apixaban effectively reduces coagulation biomarkers over 12 weeks in patients with acute DVT, similar to standard LMWH/VKA therapy.
Answers are grounded in this paper and cite their sources.
Apixaban matches LMWH/VKA in D-dimer reduction for acute DVT; confirms comparable effects on coagulation biomarkers.
In patients with acute deep-vein thrombosis (DVT), apixaban, a direct oral factor Xa inhibitor, showed efficacy and safety similar to low-molecular-weight heparin followed by vitamin K antagonist (LMWH/VKA). We evaluated biomarkers of coagulation activity in relation to treatment dose, duration and clinical outcome. Patients (N = 520) with symptomatic DVT were randomised to receive apixaban (5 mg bid, 10 mg bid or 20 mg qd) or LMWH/VKA for 12 weeks. Plasma D-dimer, prothrombin fragment 1+2 (F1+2) and thrombin-antithrombin complex (TAT) levels were measured at baseline, and weeks 3 and 12 after treatment. Median plasma levels of D-dimer, F1+2 and TAT were elevated at baseline. At weeks 3 and 12, biomarker levels were normalised in most patients in all treatment groups, consistent with the low rate of venous thromboembolism (VTE) observed. Median reduction in D-dimer was similar in all treatment groups; percentage of patients with D-dimer above upper limit of normal decreased from 95% to 24-40% at week 12. F1+2 decline was greater with LMWH/VKA than apixaban. F1+2 in the apixaban groups changed to a similar extent (>84% of patients had F1+2 within reference range at week 12). Magnitude of TAT reduction was not quantifiable. In conclusion, levels of coagulation biomarkers decreased over 12 weeks of treatment with apixaban or LMWH/VKA in most patients with acute VTE. Baseline D-dimer and F1+2 were higher in patients with recurrent symptomatic VTE than in those without. Plasma levels of coagulation biomarkers did not appear to correlate with total bleeding events.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: